Tumor characterization by ultrasound-release of multiple protein and microRNA biomarkers, preclinical and clinical evidence

We have previously shown that low frequency ultrasound can release biomarkers from cells into the murine circulation enabling an amplification and localization of the released biomarker that could be used as a blood-based method to detect cancer earlier and monitor therapy. In this study, we further demonstrate that this technique could be used for characterization of tumors and/or identification of cellular masses of unknown origin due to the release of multiple protein and nucleic acid biomarkers in cells in culture, mice and patients. We sonicated colon (LS174T) and prostate (LNCaP) cancer cell lines in culture at a low frequency of 1 MHz and show that there were several-fold changes in multiple protein and microRNA (miRNA) abundance with treatment at various intensities and time. This release was dependent on the duration and intensity of the sonication for both cell lines. Significant increased release in biomarkers was also observed following tumor sonication in living mice bearing subcutaneous LS174T cell line xenografts (for proteins and nucleic acids) and in an experimental LS174T liver tumor model (for proteins only). Finally, we demonstrated this methodology of multiple biomarker release in patients undergoing ablation of uterine fibroids using MR guided high intensity focused ultrasound. Two protein biomarkers significantly increased in the plasma after the ultrasound treatment in 21 samples tested. This proof that ultrasound-amplification method works in soft tissue tumor models together with biomarker multiplexing, could allow for an effective non-invasive method for identification, characterization and localization of incidental lesions, cancer and other disease. Pre-treatment quantification of the biomarkers, allows for individualization of quantitative comparisons. This individualization of normal marker levels in this method allows for specificity of the biomarker-increase to each patient, tumor or organ being studied.

[1]  F. Starr,et al.  Release of Cell-free MicroRNA Tumor Biomarkers into the Blood Circulation with Pulsed Focused Ultrasound: A Noninvasive, Anatomically Localized, Molecular Liquid Biopsy. , 2017, Radiology.

[2]  A. Napoli,et al.  Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study , 2017, European Radiology.

[3]  Hsin-Yao Wang,et al.  Cancer screening through a multi-analyte serum biomarker panel during health check-up examinations: Results from a 12-year experience. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[4]  J. Bu,et al.  Prognostic Role of MicroRNA-200c-141 Cluster in Various Human Solid Malignant Neoplasms , 2015, Disease markers.

[5]  S. Duffy,et al.  Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma , 2015, Clinical Cancer Research.

[6]  N. Miller,et al.  A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group , 2015, Journal of clinical medicine.

[7]  P. Gibbs,et al.  Blood-Based Protein Biomarker Panel for the Detection of Colorectal Cancer , 2015, PloS one.

[8]  Jianxiong Cui MiR-16 family as potential diagnostic biomarkers for cancer: a systematic review and meta-analysis. , 2015, International journal of clinical and experimental medicine.

[9]  Mee-Ran Kim,et al.  Usefulness of CA125 in the differential diagnosis of uterine adenomyosis and myoma. , 2015, European journal of obstetrics, gynecology, and reproductive biology.

[10]  P. Bottoni,et al.  CA 19-9: Biochemical and Clinical Aspects. , 2015, Advances in experimental medicine and biology.

[11]  R. Scatena,et al.  Cancer Biomarkers: A Status Quo. , 2015, Advances in experimental medicine and biology.

[12]  J. Trachtenberg,et al.  Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic. , 2014, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[13]  K. Loughlin PSA velocity: a systematic review of clinical applications. , 2014, Urologic oncology.

[14]  K. Wallace,et al.  Enodthelin 1 Is Elevated in Plasma and Explants From Patients Having Uterine Leiomyomas , 2014, Reproductive Sciences.

[15]  H. Taylor,et al.  MicroRNA and gynecological reproductive diseases. , 2014, Fertility and sterility.

[16]  Inyoul Y. Lee,et al.  Issues and Prospects of microRNA-Based Biomarkers in Blood and Other Body Fluids , 2014, Molecules.

[17]  C. Tempany,et al.  Magnetic Resonance–Guided Focused Ultrasound for Patients With Painful Bone Metastases: Phase III Trial Results , 2014, Journal of the National Cancer Institute.

[18]  M. Anzidei,et al.  Magnetic Resonance-Guided Focused Ultrasound Ablation in Abdominal Moving Organs: A Feasibility Study in Selected Cases of Pancreatic and Liver Cancer , 2014, CardioVascular and Interventional Radiology.

[19]  B. Győrffy,et al.  Biomarkers for systemic therapy in ovarian cancer. , 2014, Current cancer drug targets.

[20]  N. Bijedic,et al.  Cancer Antigens (CEA and CA 19-9) as Markers of Advanced Stage of Colorectal Carcinoma , 2013, Medical archives.

[21]  M. Reiser,et al.  Magnetic Resonance Imaging–Guided Focused Ultrasound Treatment of Symptomatic Uterine Fibroids: Impact of Technology Advancement on Ablation Volumes in 115 Patients , 2013, Investigative radiology.

[22]  R. Zemp,et al.  Microbubble-enhanced ultrasound liberation of mRNA biomarkers in vitro. , 2013, Ultrasound in medicine & biology.

[23]  Carlo Catalano,et al.  Real-time magnetic resonance-guided high-intensity focused ultrasound focal therapy for localised prostate cancer: preliminary experience. , 2013, European urology.

[24]  Krzysztof R. Gorny,et al.  MR-Guided Focused Ultrasound for the Treatment of Uterine Fibroids , 2013, CardioVascular and Interventional Radiology.

[25]  E. Chu,et al.  Establishment of an orthotopic transplantation tumor model of hepatocellular carcinoma in mice. , 2012, World journal of gastroenterology.

[26]  V. Chennathukuzhi,et al.  Role of microRNA-21 and programmed cell death 4 in the pathogenesis of human uterine leiomyomas. , 2012, Fertility and sterility.

[27]  V. Jaishree,et al.  Nanotechnology: A Revolution in Cancer Diagnosis , 2012, Indian Journal of Clinical Biochemistry.

[28]  V. Baev,et al.  Characterization of the uterine leiomyoma microRNAome by deep sequencing. , 2012, Genomics.

[29]  Sanjiv S Gambhir,et al.  Mathematical Model Identifies Blood Biomarker–Based Early Cancer Detection Strategies and Limitations , 2011, Science Translational Medicine.

[30]  Kathleen A Stringer,et al.  The emerging field of quantitative blood metabolomics for biomarker discovery in critical illnesses. , 2011, American journal of respiratory and critical care medicine.

[31]  W. Fan,et al.  Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy , 2011, International journal of nanomedicine.

[32]  E. Kroh,et al.  Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma , 2011, Proceedings of the National Academy of Sciences.

[33]  Betty Y. S. Kim,et al.  Current concepts: Nanomedicine , 2010 .

[34]  Jonathan A. Kopechek,et al.  Calibration of the 1-MHz Sonitron ultrasound system. , 2010, Ultrasound in medicine & biology.

[35]  C. Pichon,et al.  Transient transmembrane release of green fluorescent proteins with sonoporation , 2010, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.

[36]  Muneesh Tewari,et al.  Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). , 2010, Methods.

[37]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[38]  A. Nunn,et al.  177Lu-AMBA Biodistribution, Radiotherapeutic Efficacy, Imaging, and Autoradiography in Prostate Cancer Models with Low GRP-R Expression , 2009, Journal of Nuclear Medicine.

[39]  Boris Murmann,et al.  Matrix-insensitive protein assays push the limits of biosensors in medicine , 2009, Nature Medicine.

[40]  Sanjiv S. Gambhir,et al.  A strategy for blood biomarker amplification and localization using ultrasound , 2009, Proceedings of the National Academy of Sciences.

[41]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[42]  K. Tsao,et al.  Elevation of CA 19‐9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis , 2007, Journal of clinical laboratory analysis.

[43]  S. Mitragotri,et al.  Ultrasound-induced cavitation: applications in drug and gene delivery , 2006, Expert opinion on drug delivery.

[44]  R. Guleria,et al.  Biomarkers in cancer screening, research and detection: present and future: a review , 2006, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[45]  B. Zetter,et al.  Cancer biomarkers: knowing the present and predicting the future. , 2005, Future oncology.

[46]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[47]  Samir Mitragotri,et al.  Healing sound: the use of ultrasound in drug delivery and other therapeutic applications , 2005, Nature Reviews Drug Discovery.

[48]  A. Kristensen,et al.  A review of the sonographic assessment of tumor metastases in liver and superficial lymph nodes. , 2004, Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association.

[49]  K. Isselbacher,et al.  CEA (carcinoembryonic antigen): Its role as a marker in the management of cancer , 2004, Journal of Cancer Research and Clinical Oncology.

[50]  D. Gianfelice,et al.  MR imaging-guided focused US ablation of breast cancer: histopathologic assessment of effectiveness-- initial experience. , 2003, Radiology.

[51]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[52]  J. Bidart,et al.  Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. , 1999, Clinical chemistry.

[53]  D. Stewart,et al.  Human endothelin-1 clearance kinetics revealed by a radiotracer technique. , 1999, The Journal of pharmacology and experimental therapeutics.

[54]  M. Becich,et al.  The biosynthesis and secretion of prostate-specific antigen in LNCaP cells. , 1997, Cancer research.

[55]  M. Gleave,et al.  Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. , 1992, Cancer research.

[56]  M. Gleave,et al.  Human prostate cancer model: Roles of growth factors and extracellular matrices , 1992, Journal of cellular biochemistry. Supplement.

[57]  S. Halpern,et al.  Carcinoembryonic antigen production, secretion, and kinetics in BALB/c mice and a nude mouse-human tumor model. , 1984, Cancer research.

[58]  T. Klug,et al.  Tumorigenicity in athymic mice of the human colon carcinoma cell line SW1116 expressing the tumor-associated antigenic determinant CA 19-9. , 1984, Cancer research.